Viveka Roychowdhury

Billed as India’s first bulk drug, chemicals and allied manufacturing parks and one of the most successful public-private…

Sun Pharma’s $12 billion acquisition of Organon will prove to be a milestone as the largest takeover by an Indian pharma company.…

Adding excipient details to QR codes of the top 300 drugs may not be a tough task. But as CDSCO plans to expand QR codes to cover…

Bharat Bhardwaj, Vice President, Asia Pacific, Agilent Technologies spoke to Viveka Roychowdhury on why Agilent has been…

As pharma companies deal with price wars, increasing regulatory heat and a volatile geopolitical situation, navigating this…

Can you briefly explain ASPA’s evolution and how the anti‑counterfeiting ecosystem has changed? ASPA as an organisation started…

What do you see as India’s role in the evolving global life sciences and biopharma value chain over the next decade? India is…

While we agree that “what got us here (an affordable generics powerhouse) will not get us there (a leader in pharma innovation)”,…

The signing of the India-EU Free Trade Agreement after almost two decades of negotiations is being hailed as the ‘mother of all…

If you were to pick one or two trends in clinical trials and research in India in 2026, what would you be looking at? What are the…